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Abstract
Background: The mechanism behind the triggering effect of fine particulate matter (PM) air
pollution on cardiovascular events remains elusive. We postulated that elevated levels of PM would
be associated with increased blood levels of inflammatory and thrombotic markers in elderly
individuals. We also hypothesized that elevated PM would increase levels of cytokines in individuals
with heart disease.
Methods: We measured these blood markers in 47 elderly individuals with (23) and without (16
COPD and 8 healthy) cardiovascular disease (CVD) on 2 or 3 mornings over a 5 or 10-day period
between February 2000 and March 2002. Blood measures were paired with residence level
outdoor PM measured by nephelometry. Analyses determined the within-individual effect of 24-
hour averaged outdoor PM on blood measures.
Results: Analyses found no statistically significant effect of a same day 10 ug/m3 increase in fine PM
on log transformed levels of CRP 1.21 fold-rise [95% CI: 0.86, 1.70], fibrinogen 1.02 fold-rise [95%
CI: 0.98, 1.06], or D-dimer 1.02 fold-rise [95% CI: 0.88, 1.17] in individuals with CVD. One-day
lagged analyses in the CVD subgroup found similar null results. These same models found no change
in these blood markers at the same-day or 1-day lag in the group without CVD. In 21 individuals
with CVD, a 10 μg/m3 increase in same-day PM was associated with a 1.3 fold-rise [95% CI: 1.1, 1.7]
in the level of monocyte chemoattractant protein-1.
Conclusion: We did not find consistent effects of low ambient levels of PM on blood measures of
inflammation or thrombosis in elderly individuals.
Background
Epidemiological studies have found associations between
elevation in levels of fine particulate matter air pollution
(PM) and risk of cardiovascular morbidity and mortality
in the elderly [1-4]. Moreover, short-term elevations in
PM2.5 have been associated with triggering the onset of
myocardial infarction and AICD discharges [5-7]. How-
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ever, the mechanism behind this triggering of cardiovas-
cular events by PM2.5 remains unclear.
The cardiac effects of air pollution may be induced by a
systemic inflammatory response [8-16]. Recent studies
indicate that ischemic heart disease is likely mediated at
least in part by inflammation [17]. Inflammation plays a
substantial role in atherogenic progression, alterations in
endothelial function and potentially mediates acute
plaque rupture [17,18]. Similarly, in vitro and animal
studies have highlighted the potential for PM2.5 to induce
a systemic inflammatory response and systemic oxidative
stress that could result in impaired endothelial function
[19,20].
Epidemiological studies have suggested that elevated fine
PM is associated with increased CRP [21] and fibrinogen
[22] levels in healthy middle-age individuals. However,
there are inconsistent findings of pollutant effect on
fibrinogen after controlled exposures to ambient PM in
healthy volunteers [14,23]. Moreover, these controlled
exposure studies to concentrated ambient PM have not
detected increased levels of interleukin-6 (IL-6), CRP or
other pro-atherogenic cytokines [13,14,23]. Last, the only
study that assessed the effect of short-term elevations in
PM levels on systemic markers of inflammation in a sus-
ceptible elderly population found no effect on IL-6 or
fibrinogen levels and inconsistent effect on CRP [24]. To
determine whether PM2.5 is associated with changes in
within-individual measures of inflammation or thrombo-
sis, we performed a repeated measures study of these
blood markers at the residence level in elderly individuals
with and without heart disease. We hypothesized that
increased levels of fine PM would be associated with intra-
individual increases in CRP levels in those with heart dis-
ease. Moreover, we postulated that endothelin-1 and IL-6
levels would be elevated on high air pollution exposure
days in individuals with pre-existing heart disease.
Methods
We performed repeated blood measures of inflammation
and thrombosis in 47 elderly individuals with and with-
out cardiovascular disease (CVD) or chronic obstructive
pulmonary disease (COPD) participating in a larger pro-
spective study on health effects of air pollution in Seattle
[25]. Briefly, subjects were monitored intensively for air
pollution exposures and health outcomes over a 10-day
period between February 2000 and May 2001, or a 5-day
period between December 2001 and March 2002. Blood
samples were collected at the subject's home at approxi-
mately the same time on two or three mornings during
this monitoring period. This blood was assayed for meas-
ures of inflammation, and thrombosis. In a subset of 21
participants with CVD, bloods were also assayed for
cytokine responses. These data were paired with outdoor
nephelometry measures of fine PM made at the individu-
als' homes. These data were further enhanced by meteor-
ological variables: hourly averages of relative humidity
(RH), and temperature; daily questionnaire responses on:
medication use (3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins), aspirin, prednisone, warfa-
rin, heparin, and clopidrogel) and clinic visits. The study
protocol was approved by the University of Washington
Human Subjects Division.
Study population
Individuals were eligible if they were living in the greater
metropolitan Seattle area and >=55 years of age. The CV
population had physician diagnosed ischemic heart dis-
ease or congestive heart failure. COPD participants had an
FEV1<70% and >40% of predicted. Subjects were
excluded if they had unstable angina, myocardial infarc-
tion, pneumonia or COPD exacerbation within 30 days of
study. Subjects were non-smokers who lived with non-
smokers.
Subject recruitment
Subjects were recruited by advertisement in senior centers
and local newspapers and from medical clinics.
Exposure measures
The primary exposure metric was 24-hour averaged fine
PM (from 8-8 am) measured at 0-day and 1-day lags prior
to blood measures. PM was measured by nephelometry
(Radiance Research, Seattle), as a light scattering coeffi-
cient, outside of the participant's residence. Nephelome-
try data correlate well with gravimetric particle
measurements in the 0.1–1.4 aerodynamic range [26]. To
allow for comparability to other studies, we calibrated the
nephelometric measure of PM against a gravimetric PM2.5
measure. In 10 individuals where outdoor nephelometry
data were not measured, we used a closest home outdoor
nephelometer to capture local PM levels. This nephelom-
eter was located within 2-miles of the subjects' residence.
A total of 18 person-days of surrogate nephelometer expo-
sure measures were used in our final analysis.
Blood measures
Blood samples were drawn from an antecubital vein from
the seated subject following the recommendations of the
International Committee for Standardization in Haema-
tology[27]. Blood samples were immediately placed on
ice and centrifuged within 2 hours. The serum was stored
at -70°C for later batched analysis.
High sensitivity C-reactive protein (CRP) was measured
using the Dade-Behring radioimmunoassay method[28].
This assay had a lower limit of detection at 0.02 mg/l. The
intra-assay coefficient of variation was less than 5%.
Fibrinogen levels were measured in citrated plasma by theEnvironmental Health 2007, 6:3 http://www.ehjournal.net/content/6/1/3
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Clauss method[29]. D-dimer was measured in citrated
plasma using an enzyme immunoassay (Diagnostica
Stago). D-dimer results are reported in ng/ml of fibrino-
gen equivalent units (FEU).
The measures of endothelin-1(ET-1), interleukin-6(IL-6),
interleukin-6 receptor (IL-6r), tumor necrosis factor-α
(TNF-α), tumor necrosis factor-receptors (p55, p75) and
monocyte chemoattractant protein-1(MCP-1) were per-
formed in duplicate using standard ELISA techniques
(R&D Systems, Minneapolis). The intra-assay coefficient
of variation for ELISA assays ranged from 2.7% for IL-6 to
5% for ET-1.
Statistical analysis
The data were analyzed using the statistical package SAS
(version 8.02, Cary NC). The inflammatory and throm-
botic measures were log transformed prior to analyses. For
ease of clinical interpretation, we present the data after the
beta coefficient has been converted to a natural scale.
Effect sizes can be interpreted as the multiplicative change
in mean outcome associated with a 10 ug/m3 increase in
fine PM.
Primary analysis
We used a mixed model with random intercepts for
unique subject-sessions (SAS Proc Mixed procedure) to
determine the within-individual effect of zero-day and
one-day lagged 24-hour averaged outdoor PM on meas-
ures of inflammation (CRP and fibrinogen) and thrombo-
sis (D-dimer) for individuals in each health group. Final
models were adjusted for age, gender, medication use,
and meteorological variables (temperature and relative
humidity as both linear and quadratic terms), and the
interaction of outdoor PM with anti-inflammatory medi-
cation use (aspirin, prednisone) and statin use were also
considered. We found no significant interaction effect of
medication use with fine PM and report only overall
effects.
Table 1: Summary of Demographic and Clinical Characteristics of Study Participants.
Variable Cardiovascular N = 23 COPD N = 16 Healthy N = 8
Age Median (range) 77 (56, 86) 80 (65, 89) 78 (66, 88)
Gender Female 10 (43%) 6 (38%) 4 (50%)
Race White 23 (100%) 16 (100%) 7 (88%)
History of MI Yes 9 (39%) 3 (19%) 0 (0%)
Diabetes Current 4 (17%) 1 (16%) 1 (13%)
Angina Current 6 (26%) 3 (19%) 0 (0%)
CHF Current 7 (29%) 0 (0%) 0 (0%)
Table 2: Summary of the 24-hour Average Pollutant Exposures Preceding Blood Measure in the Study Participants.
Variable 
(unit)
N Min 25% 50% 75% 90% Max
aOutdoor PM2.5 
(μg/m3)
Subject-days 133 1. 3 5.2 7.7 11.5 19.9 33.9
Session 23 0.7 4.0 6.4 9.7 17.1 23.7
Subject-
sessionb
44 0.06 2.5 4.7 9.4 16.5 23.7
aIndoor PM2.5 
(μg/m3)
Subject-days 107 1.3 5.4 7.7 12.1 16.0 81.4
Central Site 
(Study-days)
NO2 (ppb) 51 0.01 0.02 0.02 0.03 0.03 0.03
Temperature 
(F)
58 35.5 41.4 45.3 50.4 57.0 67.8
Relative 
Humidity
58 55.5 76.0 82.1 87.5 94.2 100.0
aRepresents PM2.5 equivalent of actual nephelometric measure averaged from 8 am on prior day to 8 am on day of study.
bSubjects with greater than two 24-hour average measures of PM2.5 equivalent during study session.
The 1-day lagged measures are very similar; therefore, they are not displayed.Environmental Health 2007, 6:3 http://www.ehjournal.net/content/6/1/3
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Secondary analysis
An analysis restricted to those with pre-existing heart dis-
ease, used a linear mixed effects model to determine the
within subject-session effect of a zero-day or one-day
lagged 10 μg/m3 increase in fine PM on the log-trans-
formed levels of MCP-1 and ET-1 after adjusting for age,
gender, medication use, temperature and relative humid-
ity (as linear and quadratic terms), and the interaction
with medication use.
Results
We performed 133 plasma measures of inflammation and
thrombosis in 47 individuals with (23) and without (16
COPD and 8 Healthy) cardiovascular disease over 23
study sessions. The overall study population was older
(median age 77, range 56–89) and 43% were female
(Table 1). The CV and non-CV study populations did not
differ by demographic factors (Table 1). The CV popula-
tion was composed of 6 individuals with heart failure and
17 individuals with ischemic heart disease without overt
heart failure. Statin drugs were used in 31% of individuals
with heart disease.
Table 2 demonstrates that the range of exposure decreased
when restricting to session and within-individual concen-
tration of outdoor PM2.5. Accounting for concentrations
measured on 133 subject-days across study sessions, the
median concentration of 24-hour averaged outdoor PM2.5
was 7.7 μg/m3 (range 1.3–33.9). Restricting exposure to
within the 23 study sessions, the within session median
24-hour averaged outdoor PM concentration was 6.4 μg/
m3 (range 0.7–23.7 μg/m3). Within individual, within ses-
sion median 24-hour averaged outdoor PM concentration
was 4.7 μg/m3(range 0.06–23.7 μg/m3). Only 6 individu-
als (4 CV and 2 non-CV) experienced an intra-session var-
iation of 24-hour averaged PM2.5 exposure of greater than
15 μg/m3.
Table 3 summarizes our measures of inflammation and
thrombosis. These data demonstrate similar thrombotic
and inflammatory marker levels in the cardiovascular,
pulmonary and healthy subgroups. Interestingly, the indi-
viduals with cardiac disease have a median value of CRP
[0.20 mg/l] that was within the lowest quintile of CRP dis-
tribution in apparently healthy elderly participants in
other studies (17). Last, the range of values of CRP, D-
dimer and fibrinogen in this study population were con-
sistent with prior results in elderly populations (30).
Our analyses found no effect of fine PM at 0-day lag on
CRP 1.2 fold-increase [95% CI: 0.9, 1.6], fibrinogen 1.0
fold-increase [95% CI: 1.0, 1.1] or D-dimer 1.1 fold-
increase [95% CI: 0.9, 1.2] in those with CV disease after
adjusting for RH and temperature. The 1-day lagged anal-
yses in the CV subgroup found similar null results, Table
4. These same models found the same null association
between fine PM and these blood measures in the healthy
and COPD subgroups, Table 4. Further stratification of
these models by covariates known to influence measures
of thrombosis including age, gender, anti-inflammatory
or anticoagulant medication use, diabetes, active angina
or CHF did not modify the null association between fine
PM and CRP, fibrinogen and D-dimer levels in the CV,
COPD or healthy subgroups, data not shown.
Moreover, using these same models, we found no effect
from a 1-ppb increase in either 0-day or 1-day lagged 24-
hour average NO2 or a 1-ppm increase in 0-day or 1-day
Table 3: Summary of Inflammatory and Thrombotic Blood Measures by Health Status
Health Status D-dimer ng/ml (median: range) CRP mg/l (median: range) Fibrinogen mg/dl (median: range)
Healthy [n = 8] 503: 353 – 2020 0.30: 0.10 – 2.0 392: 313 – 511
COPD [n = 16] 427: 163 – 1164 0.60: 0.10 – 3.5 425: 327 – 617
Cardiovascular [n = 23] 368: 162 – 4359 0.20: 0.02 – 14.5 403: 268 – 674
Table 4: Fine PM effect on blood markers of inflammation and thrombosis in study participants.+
Disease Status 24-hr average PM lag-day CRP Fold-rise (95% CI) Fibrinogen Fold-rise (95% 
CI)
D-dimer Fold-rise (95% CI)
CV 0-day 1.19 (0.86, 1.64) 1.02 (0.97, 1.07) 1.05 (0.91, 1.22)
1-day 1.25 (0.97, 1.58) 1.01 (0.97, 1.05) 1.04 (0.93, 1.15)
COPD 0-day 0.93 (0.48, 1.79) 1.00 (0.91, 1.08) 1.04 (0.93, 1.17)
1-day 0.69 (0.34, 1.42) 1.05 (0.97, 1.13) 1.10 (0.95, 1.28)
Healthy 0-day 0.97 (0.48, 1.07) 0.93 (0.88, 1.00) 1.02 (0.80, 1.31)
1-day 1.01 (0.85, 1.19) 0.88 (0.81, 0.95) 1.10 (0.76, 1.58)
+The models control for relative humidity and temperature.
†Model assesses affect of a 10 ug/m3 increase in fine PM on blood markers.Environmental Health 2007, 6:3 http://www.ehjournal.net/content/6/1/3
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lagged 24-hour average CO level on inflammatory or
thrombotic measures in the CV, COPD or healthy sub-
groups, data not shown.
Our final model did not find a significant effect of a same
day 10 ug/m3 increase in fine PM on measures of CRP
1.21 fold-rise [95% CI: 0.86, 1.70], fibrinogen 1.02 fold-
rise [95% CI: 0.98, 1.06], or D-dimer 1.02 fold-rise [95%
CI: 0.88, 1.17] in individuals with pre-existing CV disease
(Table 5). These same models found no change in these
blood markers in the COPD or healthy subgroups, (Table
5). Moreover, stratifying by statin use did not modify the
absence of association between 0-day or 1-day lagged
increased PM and levels of CRP or fibrinogen in CV,
COPD or healthy subgroups, data not shown.
We analyzed PM effect on cytokine levels in 21 individu-
als with known cardiac disease by pairing 59 repeated-
measures of endothelin-1, IL-6 and IL-6 receptor, TNF-α
and TNF-α receptors [p55, p75], and MCP-1 to outdoor
residence level measures of PM. The median level of MCP-
1 was 156 pg/ml (range: 66–647 pg/ml) and the median
level of endothelin-1 was 3.6 pg/ml (range: 1.5–6.6 pg/
ml). We were unable to assess the effect of PM on levels of
TNF-α and IL-6 as most values were below the limit of
detection of our assays, which were 2.0 pg/ml and 0.3 pg/
ml, respectively.
Our analyses found that a 10 μg/m3 increase in zero-day
outdoor PM was associated with a 1.3 fold increase [95%
CI: 1.1, 1.7] in the level of MCP-1 in these individuals
after controlling for age, gender, RH, temperature and
medication use (Table 6). This effect was not evident at
the 1-day lag exposure 1.0 [95% CI: 0.9, 1.3]. A 10 μg/m3
increase in PM was not associated with a significant
increase in ET-1 levels at the 0-day lagged exposure 1.0
[95% CI: 0.8, 1.2] and 1-day lagged exposures 1.1 [95%
CI: 0.9, 1.2] (Table 6). The use of statin medications did
not modify the association between the same day fine PM
levels and levels of MCP-1 or ET-1.
Discussion
Our study was unable to find consistent associations
between increased PM2.5 levels and elevations in blood
indices of inflammation or thrombosis. Our finding of an
increased MCP-1 level from a 10 ug/m3 increase in fine
PM should be interpreted with caution given the multiple
analyses conducted in this project.
Although in vitro and animal studies support an inflam-
matory mechanism of PM effect [31-34], it is possible that
PM exerts cardiac effect through direct interaction with the
heart and vascular endothelium [35] or through neuro-
genic mechanisms [15,36]. We chose our blood measures
to reflect the production of acute-phase proteins (CRP and
fibrinogen) and circulating inflammatory mediators
(cytokines) that characterize the systemic inflammatory
response. Therefore, our null results likely reflect the small
variation in PM2.5 exposure over the study sessions; inad-
equate control for personal and medication effects on
blood measures; and within-subject physiologic variabil-
ity of these blood markers.
Table 5: Change in markers of inflammation and thrombosis in participants from a 10 ug/m3 increase in PM2.5.+
Disease Status 24-hr average Outdoor PM 
lag-day
CRP Fold-rise (95% CI) Fibrinogen Fold-rise (95% 
CI)
D-dimer Fold-rise (95% CI)
CV 0-day 1.21 (0.86, 1.70) 1.02 (0.98, 1.06) 1.02 (0.88, 1.17)
1-day 1.25 (0.97, 1.58) 1.0 (0.97, 1.03) 1.03 (0.93, 1.15)
COPD 0-day 0.93 (0.48, 1.80) 1.0 (0.91, 1.09) 1.04 (0.93, 1.16)
1-day 0.69 (0.33, 1.46) 1.08 (0.99, 1.17) 1.09 (0.94, 1.27)
Healthy 0-day 0.98 (0.88, 1.08) 0.94 (0.87, 1.01) 0.95 (0.79, 1.14)
1-day 1.01 (0.84, 1.21) 0.99 (0.88*, 1.17) 0.97 (0.71, 1.31)
+ The model is adjusted for age, gender, medication use, temperature, and relative humidity.
Table 6: Effect of a 10 ug/m3 increase in PM2.5 on cytokine levels of participants with cardiovascular disease.+
Lag-day MCP-1 Fold-rise (95% CI) Endothelin-1 Fold-rise (95% CI)
0-day 1.3 (1.1, 1.7) 1.1 (0.8, 1.2)
1-day 1.0 (0.9, 1.3) 1.1 (0.9, 1.2)
+ Models were adjusted for age, gender, medication use, temperature, and relative humidity.
* The majority of measures of TNF-alpha and IL-6 were below the limit of detection of assays; therefore, we were unable to determine effect of PM 
on these markers.Environmental Health 2007, 6:3 http://www.ehjournal.net/content/6/1/3
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Small excursions in fine PM levels may not result in appre-
ciable changes in blood measures of inflammation or
thrombosis even in susceptible individuals. Our null find-
ings for IL-6, CRP and fibrinogen are consistent with a
repeated blood measures study in 108 elderly individuals
performed over an 18-month interval by Seaton that only
found consistent increases in red blood cell indices
(packed cell volume) from the multiple blood measures
of inflammation and thrombosis [24]. Our results are also
in agreement with controlled exposure studies to ambient
PM in healthy volunteers that find no effect of PM on mul-
tiple blood markers of inflammation and thrombosis
with the exception of fibrinogen. Our results contrast with
results from a cohort study of 631 middle-age men in Ger-
many' that found a greater than 2-fold risk of CRP
level>99% (10.8 mg/l) from a 5-day average 26 ug/m3
increase in total suspended particles (TSP)[21]. Due to
differences in exposure measures (3-day and 5-day mov-
ing averages) and analytic method in this study, it is diffi-
cult to make a direct comparison of relative effect of PM
between studies. Our results are consistent with a PM
effect on CRP between a 20 percent decline to a 70 percent
increase in blood measure.
The absence of PM effect on blood markers of inflamma-
tion and thrombosis at exposure levels of 50–120 ug/m3
PM2.5 in both healthy and asthmatic young volunteers
suggests that an inflammatory effect of fine PM may be
limited to susceptible populations [14]. Despite their
underlying medical conditions, our subjects did not gen-
erally have elevated levels of inflammatory measures over
the study. This may suggests that our small sample of eld-
erly individuals are not those at greatest risk of PM effect.
Epidemiological studies suggest that acute bronchitis, and
pneumonia potentiate the cardiac effect of PM in individ-
uals with underlying cardiovascular and pulmonary dis-
ease [37]. The mechanism behind the augmentation of
PM effect is unclear, but may be explained by changes in
transcription of pro-inflammatory genes secondary to the
acute infection. Moreover, we speculate that the null
results could reflect differences in genetic determinants of
susceptibility to PM. Individuals with GSTM1 null and
GSTP1 1/1 genotypes have demonstrated increased sensi-
tivity to diesel particulate matter and environmental
tobacco smoke suggesting that common genetic variants
may influence susceptibility to PM [38]. Unfortunately,
our small sample size does not permit further gene-envi-
ronment analyses as a source of the null results.
The inherent physiologic variability of our inflammatory
and thrombotic measures may outweigh the small effects
from PM even after restricting our change in blood meas-
ure to a within-person, within-session effect. We may have
inadequately controlled for disease-related (silent
ischemia, CHF and COPD exacerbations, and medication
use) and non-disease related factors (stress, depression)
that are known to transiently increase the levels of inflam-
matory and thrombotic markers independently of PM
effect.
Last, the higher fraction of secondary aerosols rich in sul-
fates and transition metals composing PM in the Euro-
pean studies may account for the difference in effect of PM
on inflammation and thrombosis between the studies.
Our study had several strengths that add to the validity of
results. It was performed in an elderly population with
and without cardiac and respiratory disease. Our intensive
residential level exposure monitoring potentially
decreased exposure misclassification. We controlled for
diurnal variation in inflammatory and thrombotic mark-
ers by performing blood measures at the same time in
each individual.
Conclusion
Our small study was unable to find a pro-inflammatory or
pro-thrombotic effect of fine PM at low ambient levels. As
the mechanism of PM effect on cardiovascular function
remains unknown, we encourage performance of systemic
measures of inflammation, thrombosis and oxidative
stress in larger panel studies of susceptible populations
and in controlled exposure studies to ambient PM in eld-
erly individuals with and without cardiac and respiratory
disease.
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